Amgen gets license.Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. said it has licensed to Amgen the fights to develop products and treatments for autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause based on a gene Human Genome Sciences discovered. Rockville, Md.-based Human Genome Sciences said it will receive an upfront payment. annual fees, milestone payments and royalties from net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight of products that Amgen develops using the fights. Treatments based on the gene could be used to treatment immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. diseases or to suppress cancer. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion